<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836677</url>
  </required_header>
  <id_info>
    <org_study_id>D5980C00019</org_study_id>
    <nct_id>NCT03836677</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD</brief_title>
  <official_title>A Randomized, Double-blind, Two Treatment, Two Period, Chronic Dosing (4 Weeks), Crossover, Multi-center Pilot Study to Evaluate the Effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycopyrronium/Formoterol Fumarate on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to&#xD;
      evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and&#xD;
      Glycopyrronium/Formoterol Fumarate (GFF) on airway dimensions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to&#xD;
      evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF), and&#xD;
      Glycopyrronium/Formoterol Fumarate (GFF), on specific image based airway volumes and&#xD;
      resistance in subjects with moderate to severe Chronic Obstructive Pulmonary Disease. In this&#xD;
      study, airway dimension parameters will be calculated for each of the active compounds.&#xD;
&#xD;
      This imaging methodology will allow an assessment of the extent of airway changes using a&#xD;
      triple combination of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and the dual&#xD;
      combination Glycopyrronium/Formoterol Fumarate (GFF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Actual">November 11, 2019</completion_date>
  <primary_completion_date type="Actual">November 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific Image-based Airway Volume (siVaw)</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Specific image-based airway volume (SiVaw) measured in mL/L. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific Image-based Airway Resistance (siRaw)</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Specific image-based airway resistance (siRaw) measured in kPa∙s. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image-based Airway Volume (iVaw)</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Image-based Airway Volume (iVaw) measured in mL. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image-based Airway Resistance (iRaw)</measure>
    <time_frame>Baseline, 29 Days</time_frame>
    <description>Image-based airway resistance (iRaw) measured in kPa∙s/L. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (Post-dose FEV1).</measure>
    <time_frame>Baseline 29 Days</time_frame>
    <description>Change from baseline in Forced Expiratory Volume in One Second (Post-dose FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Residual Capacity (FRC)</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Change from baseline in Functional residual capacity (FRC).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>BGF-GFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFF-BGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>BGF</intervention_name>
    <description>Treatment with Budesonide/Glycopyrronium/FormoterolFumarate</description>
    <arm_group_label>BGF-GFF</arm_group_label>
    <arm_group_label>GFF-BGF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>GFF</intervention_name>
    <description>Treatment with Glycopyrronium/Formoterol Fumarate</description>
    <arm_group_label>BGF-GFF</arm_group_label>
    <arm_group_label>GFF-BGF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject must be 40 years to ≤80 years of age inclusive, at the time of signing the informed&#xD;
        consent form at Visit 1.&#xD;
&#xD;
          -  COPD Diagnosis: Subjects with an established clinical history of COPD&#xD;
&#xD;
          -  Screening clinical laboratory tests must be acceptable to the Investigator.&#xD;
&#xD;
          -  Screening ECG must be acceptable to the Investigator&#xD;
&#xD;
          -  Individual Compliance: Subjects must be willing to remain at the study center as&#xD;
             required per protocol to complete all visit assessments&#xD;
&#xD;
          -  Patients should be on scheduled maintenance treatment with one or more inhaled&#xD;
             bronchodilator therapies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As judged by the investigator, any evidence of significant diseases other than COPD,&#xD;
             i.e., disease or condition which, in the investigator's opinion makes it undesirable&#xD;
             for the subject to participate in the trial.&#xD;
&#xD;
          -  Spirometry Performance:&#xD;
&#xD;
               1. Subjects who cannot perform acceptable spirometry, i.e., meet ATS/ERS&#xD;
                  acceptability criteria.&#xD;
&#xD;
               2. Repeatability: Subjects who cannot perform technically acceptable spirometry in&#xD;
                  accordance with ATS repeatability criteria&#xD;
&#xD;
          -  Cancer: Subjects who have cancer that has not been in complete remission for at least&#xD;
             five years.&#xD;
&#xD;
          -  Substance Abuse: Subjects, who in the opinion of the Investigator, significantly abuse&#xD;
             alcohol or drugs&#xD;
&#xD;
          -  Subjects who in the opinion of the investigator are unable to abstain from prohibited&#xD;
             medications including LABA/LAMAs/ICS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erpent</city>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5980C00019&amp;amp;attachmentIdentifier=a5d5dc54-7197-4031-9e83-0480baeaa3f2&amp;amp;fileName=d5980c00019-sap-ed-2_Redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>Statistical Analysis Plan (SAP)</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5980C00019&amp;amp;attachmentIdentifier=603a22eb-76ce-4e33-af2d-84d7b45e7bb8&amp;amp;fileName=d5980c00019-csp-v3_Redacted-v1.pdf&amp;amp;versionIdentifier=</url>
    <description>CSP</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <results_first_submitted>November 10, 2020</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2021</results_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03836677/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03836677/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study randomized 23 subjects at 4 study centers (1 center in Belgium and 3 centers in the Netherlands) from Feb 2019 to Nov 2019.</recruitment_details>
      <pre_assignment_details>Subjects were randomized into 1 of 2 treatment sequences. Sequence 1 received BGF MDI in Period 1 followed by GFF MDI in Period 2. Sequence 2 received GFF MDI in Period 1 followed by BGF MDI in Period 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BGF MDI/GFF MDI</title>
          <description>Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation followed by Washout and then Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
        </group>
        <group group_id="P2">
          <title>GFF MDI/BGF MDI</title>
          <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation followed by Washout and then Budesonide/Glycopyrronium/Formoterol Metered Dose Inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population - all subjects who were randomized to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>ITT Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>ITT Population</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>ITT Population</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>ITT Population</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Specific Image-based Airway Volume (siVaw)</title>
        <description>Specific image-based airway volume (SiVaw) measured in mL/L. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.</description>
        <time_frame>Baseline, Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI</title>
            <description>Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI</title>
            <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Image-based Airway Volume (siVaw)</title>
          <description>Specific image-based airway volume (SiVaw) measured in mL/L. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.</description>
          <population>ITT Population</population>
          <units>Ratio to baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.38" upper_limit="2.13"/>
                    <measurement group_id="O2" value="1.53" lower_limit="1.28" upper_limit="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric Mean ratio to baseline</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test.</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specific Image-based Airway Resistance (siRaw)</title>
        <description>Specific image-based airway resistance (siRaw) measured in kPa∙s. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.</description>
        <time_frame>Baseline, Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI</title>
            <description>Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI</title>
            <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Image-based Airway Resistance (siRaw)</title>
          <description>Specific image-based airway resistance (siRaw) measured in kPa∙s. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.</description>
          <population>ITT Population</population>
          <units>Ratio to baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.39" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.40" upper_limit="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Image-based Airway Volume (iVaw)</title>
        <description>Image-based Airway Volume (iVaw) measured in mL. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.</description>
        <time_frame>Baseline, Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI</title>
            <description>Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI</title>
            <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Image-based Airway Volume (iVaw)</title>
          <description>Image-based Airway Volume (iVaw) measured in mL. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.</description>
          <population>ITT Population</population>
          <units>Ratio to baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" lower_limit="1.37" upper_limit="2.11"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.26" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Image-based Airway Resistance (iRaw)</title>
        <description>Image-based airway resistance (iRaw) measured in kPa∙s/L. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.</description>
        <time_frame>Baseline, 29 Days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI</title>
            <description>Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI</title>
            <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Image-based Airway Resistance (iRaw)</title>
          <description>Image-based airway resistance (iRaw) measured in kPa∙s/L. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.</description>
          <population>ITT Population</population>
          <units>Ratio to baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.40" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.40" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (Post-dose FEV1).</title>
        <description>Change from baseline in Forced Expiratory Volume in One Second (Post-dose FEV1).</description>
        <time_frame>Baseline 29 Days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI</title>
            <description>Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI</title>
            <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (Post-dose FEV1).</title>
          <description>Change from baseline in Forced Expiratory Volume in One Second (Post-dose FEV1).</description>
          <population>ITT Population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.346" lower_limit="0.182" upper_limit="0.509"/>
                    <measurement group_id="O2" value="0.273" lower_limit="0.140" upper_limit="0.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test.</method_desc>
            <param_type>Mean Change from Baseline</param_type>
            <param_value>0.346</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.182</ci_lower_limit>
            <ci_upper_limit>0.509</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test.</method_desc>
            <param_type>Mean Change from Baseline</param_type>
            <param_value>0.273</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.140</ci_lower_limit>
            <ci_upper_limit>0.405</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Residual Capacity (FRC)</title>
        <description>Change from baseline in Functional residual capacity (FRC).</description>
        <time_frame>Baseline, Day 29</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI</title>
            <description>Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI</title>
            <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Residual Capacity (FRC)</title>
          <description>Change from baseline in Functional residual capacity (FRC).</description>
          <population>ITT Population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" lower_limit="-0.77" upper_limit="0.21"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-0.81" upper_limit="-0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2515</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test.</method_desc>
            <param_type>Mean ratio to baseline</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0040</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test.</method_desc>
            <param_type>Mean ratio to baseline</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from visit 2 throughout the treatment period and including the follow-up period telephone call.</time_frame>
      <desc>The Safety Population was defined as all subjects who were randomized to treatment and received at least one dose of study treatment. Serious adverse events were collected visit 2 throughout the treatment period and including the follow-up period telephone call.</desc>
      <group_list>
        <group group_id="E1">
          <title>BGF MDI</title>
          <description>Budoesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
        </group>
        <group group_id="E2">
          <title>GFF MDI</title>
          <description>Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca AB</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

